Phase 1
Retrospective benchmarking, calibration and subgroup checks.
Ariadne Health · Precision guidance
We help you keep taking buprenorphine
3 out of 5 people who start buprenorphine stop within 6 months.
Ariadne identifies strategies that helped others in your situation decrease unmanaged symptoms and stay on treatment.
Buprenorphine does not treat all aspects of opioid use disorder and may have side effects.
Demo login: demo / demo123. Synthetic data, read-only, with a guided tour.
About
Ariadne Health is a health technology company developing AI-powered tools that improve adherence to evidence-based treatments by transforming patient-reported experiences into transparent, symptom-specific guidance.
- 112,000
- unique patient reports
- 12
- recommendations
- 10
- symptoms covered
- Symptom-specific guidance
- Evidence-filtered recommendations
- Patient-reported experience analysis
- Treatment adherence support
- Transparent evidence summaries
How it works
Ariadne converts patient experience signals into interpretable clinical decision support, validated through a staged retrospective → prospective pathway.
Data acquisition
Publicly available patient narratives from online forums.
Clinical annotation
Domain experts label symptoms, adverse effects, adherence barriers and coping strategies — creating a high-quality training corpus.
NLP extraction
Entity extraction, normalization, temporality, negation and distress markers using curated ontologies and model-assisted pipelines.
Pragmatic engine
Identifies remedies specifically and repeatedly described to have a narrow spectrum of effects.
User interface
Patient guidance and clinician dashboards.
Evidence
Ariadne is being validated as a clinical decision support that increases adherence to buprenorphine treatment at 6 months.
Phase 2
Prospective pilot: workflow integration, usability and safety review.
Phase 3
Pragmatic study: retention and cost outcomes versus standard care.
Regulatory posture. Initial direct-to-consumer marketing as patient guidance, with a clear roadmap to regulated clinical decision support software (CDS) for clinicians.
This prototype is for demonstration and pilot discussions and does not provide medical advice.
Team
Built by clinicians and scientists at the intersection of addiction care, toxicology and applied AI.
Michael Chary, MD, PhD
Founder and CEO
Assistant Professor at Weill Cornell. Clinician-scientist in medical toxicology with experience building clinical decision support and real-world evidence pipelines.
- Clinical and research leadership in decision support
- Applied NLP/ML for real-world data
- Embedded in academic-clinical networks
Alexander Fortenko, MD
Customer Engagement
Assistant Professor at Weill Cornell with leadership experience in care innovation, telemedicine and hospital-at-home operations.
- Director of Clinical Innovation
- Director of Hospital at Home for NewYork-Presbyterian
- 4 years of experience in telemedicine
Benjamin Sprouse, MBA
Business Development
Medical student with startup and commercialization experience.
- Founded PsychGigs, which generated revenue after two years
Advisors
- Joseph Habboushe, MD, MBA — creator of MDCalc
- Gregory Ray, PhD — Professor of Entrepreneurship, Cornell University
Our journey
Ariadne began as an effort to better understand what patients actually experience during opioid withdrawal and recovery, and to turn those insights into practical support tools.
- 2022–25
Theoretical foundation
Dr. Chary conceived of applying linguistics and information theory to real-world data to understand patterns of medication use.
- 2025
Concept formation
Ariadne was conceived to address a gap in the treatment of opioid use disorder: patients do not keep taking a life-saving medication because of symptoms and barriers to adherence.
- 2025
Team development
Dr. Chary and Mr. Sprouse meet at i4SUD, sponsored by the National Institute on Drug Abuse, and begin collaborating on Ariadne. They are later joined by Dr. Fortenko.
- 2026
Pilot support
Awarded the NIDA $100K SUD Startup Challenge.
- 2026
Prototype is live
Live with 112,000 unique reports, driving 12 recommendations across 10 symptoms.
- Next
Clinical and real-world deployment
Test in real-world settings and refine how it supports patients, clinicians and partner organizations.
Partner with us
We’re building an interpretable clinical decision support platform to improve retention in opioid use disorder treatment. We collaborate with clinics, health systems, payers, researchers and aligned investors.
For partners — pilot
Pilot goals
- Calibration in your population
- Workflow fit, usability and safety review
- Early signals of improved adherence
What we need
- Clinical champion and operational point of contact
- De-identified export or secure evaluation
- Feedback on workflow and outcomes
What you get
- Early access to the platform and dashboards
- Site-specific performance report
- Input on future versions
- Option for co-authorship
For investors — seed / pilot stage
Our mission is simple: to help people stay on life-saving treatment by making side-effect management practical, personalized and reliable. We’re starting with buprenorphine because that’s where the failure rate is highest and the consequences are most severe.
Investment thesis
Retention is the key failure mode in buprenorphine care. Ariadne uses real-world patient experience signals to identify dropout risk early, map drivers to evidence-linked interventions, and deliver interpretable outputs suitable for clinical workflow and governance.
What’s built
- Symptom intelligence and remedy mapping
- Clinician-facing views
- Role-gated prototype
Next milestones
- Retrospective validation package
- 2–3 clinic pilots
- Prospective workflow study
What we’re looking for
- Strategic seed partners with digital health and regulated-AI experience
- Introductions to OUD clinics and payers for pilots
- Guidance on reimbursement and enterprise go-to-market
We can also share an updated investor memo and data-room links.